X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs IPCA LABS - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS IPCA LABS NOVARTIS/
IPCA LABS
 
P/E (TTM) x 328.0 28.1 1,168.1% View Chart
P/BV x 36.4 3.3 1,091.8% View Chart
Dividend Yield % 1.3 0.1 892.2%  

Financials

 NOVARTIS   IPCA LABS
EQUITY SHARE DATA
    NOVARTIS
Mar-18
IPCA LABS
Mar-18
NOVARTIS/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs758695 109.0%   
Low Rs579400 144.8%   
Sales per share (Unadj.) Rs228.4260.2 87.8%  
Earnings per share (Unadj.) Rs31.719.0 167.3%  
Cash flow per share (Unadj.) Rs32.833.1 99.1%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.50.2 819.3%  
Book value per share (Unadj.) Rs297.1213.0 139.5%  
Shares outstanding (eoy) m24.69126.20 19.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.1 139.1%   
Avg P/E ratio x21.128.9 73.0%  
P/CF ratio (eoy) x20.416.6 123.1%  
Price / Book Value ratio x2.22.6 87.5%  
Dividend payout %31.55.3 597.8%   
Avg Mkt Cap Rs m16,50569,120 23.9%   
No. of employees `0000.713.3 5.0%   
Total wages/salary Rs m1,4457,359 19.6%   
Avg. sales/employee Rs Th8,441.32,477.4 340.7%   
Avg. wages/employee Rs Th2,163.6555.2 389.7%   
Avg. net profit/employee Rs Th1,173.1180.6 649.4%   
INCOME DATA
Net Sales Rs m5,63932,836 17.2%  
Other income Rs m1,718418 411.1%   
Total revenues Rs m7,35733,254 22.1%   
Gross profit Rs m-634,505 -1.4%  
Depreciation Rs m251,777 1.4%   
Interest Rs m55240 23.0%   
Profit before tax Rs m1,5752,905 54.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m792511 154.9%   
Profit after tax Rs m7842,394 32.7%  
Gross profit margin %-1.113.7 -8.1%  
Effective tax rate %50.317.6 285.7%   
Net profit margin %13.97.3 190.6%  
BALANCE SHEET DATA
Current assets Rs m9,52219,455 48.9%   
Current liabilities Rs m3,29610,076 32.7%   
Net working cap to sales %110.428.6 386.5%  
Current ratio x2.91.9 149.6%  
Inventory Days Days3798 37.4%  
Debtors Days Days2867 42.5%  
Net fixed assets Rs m4620,260 0.2%   
Share capital Rs m123252 48.9%   
"Free" reserves Rs m7,21326,633 27.1%   
Net worth Rs m7,33626,886 27.3%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m11,10541,173 27.0%  
Interest coverage x29.513.1 225.2%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.50.8 63.7%   
Return on assets %7.66.4 118.1%  
Return on equity %10.78.9 119.9%  
Return on capital %22.210.8 206.5%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m6115,642 0.4%   
Fx outflow Rs m3,6304,884 74.3%   
Net fx Rs m-3,57010,759 -33.2%   
CASH FLOW
From Operations Rs m1,6103,411 47.2%  
From Investments Rs m687-1,354 -50.7%  
From Financial Activity Rs m-2,677-1,304 205.2%  
Net Cashflow Rs m-380753 -50.4%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 11.4 17.5%  
FIIs % 1.6 25.3 6.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.4 123.6%  
Shareholders   41,647 36,892 112.9%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SUN PHARMA  DR. REDDYS LAB  TORRENT PHARMA  UNICHEM LAB  MERCK LTD  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - DIVIS LABORATORIES COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS